pyrazines has been researched along with scio-469 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, KC; Chakravarty, S; Dugar, S; Haghnazari, E; Henson, M; Hideshima, T; Higgins, LS; Kapoun, AM; Kerr, I; Luedtke, G; Ma, JY; Mavunkel, B; Medicherla, S; Navas, TA; Nguyen, AN; O'Young, G; Perumattam, J; Protter, AA; Reddy, M; Schreiner, GF; Stebbins, EG | 1 |
Walker, K | 1 |
2 other study(ies) available for pyrazines and scio-469
Article | Year |
---|---|
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; In Vitro Techniques; Indoles; Injections, Intravenous; Leupeptins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2006 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines | 2007 |